Literature DB >> 33872570

Discovery of a AHR pelargonidin agonist that counter-regulates Ace2 expression and attenuates ACE2-SARS-CoV-2 interaction.

Michele Biagioli1, Silvia Marchianò1, Rosalinda Roselli2, Cristina Di Giorgio1, Rachele Bellini1, Martina Bordoni1, Anna Gidari1, Samuele Sabbatini1, Daniela Francisci1, Bianca Fiorillo2, Bruno Catalanotti2, Eleonora Distrutti3, Adriana Carino1, Angela Zampella2, Gabriele Costantino4, Stefano Fiorucci5.   

Abstract

The severe acute respiratory syndrome (SARS)-CoV-2 is the pathogenetic agent of Corona Virus Induced Disease (COVID)19. The virus enters the human cells after binding to the angiotensin converting enzyme (ACE)2 receptor in target tissues. ACE2 expression is induced in response to inflammation. The colon expression of ACE2 is upregulated in patients with inflammatory bowel disease (IBD), highlighting a potential risk of intestinal inflammation in promoting viral entry in the human body. Because mechanisms that regulate ACE2 expression in the intestine are poorly understood and there is a need of anti-SARS-CoV-2 therapies, we have settled to investigate whether natural flavonoids might regulate the expression of Ace2 in intestinal models of inflammation. The results of these studies demonstrated that pelargonidin activates the Aryl hydrocarbon Receptor (AHR) in vitro and reverses intestinal inflammation caused by chronic exposure to high fat diet or to the intestinal braking-barrier agent TNBS in a AhR-dependent manner. In these two models, development of colon inflammation associated with upregulation of Ace2 mRNA expression. Colon levels of Ace2 mRNA were directly correlated with Tnf-α mRNA levels. Molecular docking studies suggested that pelargonidin binds a fatty acid binding pocket on the receptor binding domain of SARS-CoV-2 Spike protein. In vitro studies demonstrated that pelargonidin significantly reduces the binding of SARS-CoV-2 Spike protein to ACE2 and reduces the SARS-CoV-2 replication in a concentration-dependent manner. In summary, we have provided evidence that a natural flavonoid might hold potential in reducing intestinal inflammation and ACE2 Induction in the inflamed colon in a AhR-dependent manner.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  ACE2; Ahr; Intestinal inflammation; NF-kB; Pelargonidin; SARS-CoV-2; TNF-α

Year:  2021        PMID: 33872570     DOI: 10.1016/j.bcp.2021.114564

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Gut-brain communication in COVID-19: molecular mechanisms, mediators, biomarkers, and therapeutics.

Authors:  Tameena Wais; Mehde Hasan; Vikrant Rai; Devendra K Agrawal
Journal:  Expert Rev Clin Immunol       Date:  2022-07-28       Impact factor: 5.124

2.  Different compounds against Angiotensin-Converting Enzyme 2 (ACE2) receptor potentially containing the infectivity of SARS-CoV-2: an in silico study.

Authors:  Behzad Shahbazi; Ladan Mafakher; Ladan Teimoori-Toolabi
Journal:  J Mol Model       Date:  2022-03-05       Impact factor: 2.172

3.  GLP-1 Mediates Regulation of Colonic ACE2 Expression by the Bile Acid Receptor GPBAR1 in Inflammation.

Authors:  Michele Biagioli; Silvia Marchianò; Rosalinda Roselli; Cristina Di Giorgio; Rachele Bellini; Martina Bordoni; Eleonora Distrutti; Bruno Catalanotti; Angela Zampella; Luigina Graziosi; Annibale Donini; Stefano Fiorucci
Journal:  Cells       Date:  2022-04-01       Impact factor: 6.600

Review 4.  Factors Modulating COVID-19: A Mechanistic Understanding Based on the Adverse Outcome Pathway Framework.

Authors:  Laure-Alix Clerbaux; Maria Cristina Albertini; Núria Amigó; Anna Beronius; Gillina F G Bezemer; Sandra Coecke; Evangelos P Daskalopoulos; Giusy Del Giudice; Dario Greco; Lucia Grenga; Alberto Mantovani; Amalia Muñoz; Elma Omeragic; Nikolaos Parissis; Mauro Petrillo; Laura A Saarimäki; Helena Soares; Kristie Sullivan; Brigitte Landesmann
Journal:  J Clin Med       Date:  2022-07-31       Impact factor: 4.964

5.  Real-World Evidence for COVID-19 Delta Variant's Effects on the Digestive System and Protection of Inactivated Vaccines from a Medical Center in Yangzhou, China: A Retrospective Observational Study.

Authors:  Wenjing Zhao; Yong Li; Ruijin Xie; Yuying Dong; Yan Wei; Ce Cheng; Scott Lowe; Chenyu Sun; Cunjin Wang; Ju Gao
Journal:  Int J Clin Pract       Date:  2022-08-19       Impact factor: 3.149

Review 6.  Therapeutic Potential of Glycosyl Flavonoids as Anti-Coronaviral Agents.

Authors:  Patrícia I C Godinho; Raquel G Soengas; Vera L M Silva
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-07
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.